Registry study observes shifting antidiabetic prescription patterns in type 2 diabetes patients, indicating clinical adoption driven by cardiovascular trials ahead of official guidelines.
In this long-term, real-world study on prescription changes in the Diabetes Registry Tyrol, we observed significant increase in SGLT-2i, metformin, gliptins and GLP-1a prescriptions. In contrast prescriptions for sulfonylureas declined significantly. Changes were consistent over the years 2012-2018. Changes in prescription patterns occurred even before the publication of international and national guidelines. Thus, physicians change their prescription practice not only based on published guidelines, but even earlier on publication of cardiovascular outcome trials.
No takes yet. Share an insight, caveat, or question.
Engler et al. (2020) studied this question.